Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Pacritinib for the treatment of patients with myelofibrosis and thrombocytopenia
John Mascarenhas
Expert Review of Hematology (2022) Vol. 15, Iss. 8, pp. 671-684
Closed Access | Times Cited: 42

Showing 1-25 of 42 citing articles:

Properties of FDA-approved small molecule protein kinase inhibitors: A 2023 update
Robert Roskoski
Pharmacological Research (2022) Vol. 187, pp. 106552-106552
Open Access | Times Cited: 239
Targeting JAK2/STAT3 for the treatment of cancer: A review on recent advancements in molecular development using structural analysis and SAR investigations
Rupali Kohal, Priya Bisht, Ghanshyam Das Gupta, et al.
Bioorganic Chemistry (2024) Vol. 143, pp. 107095-107095
Closed Access | Times Cited: 14
New drug approvals for 2022: Synthesis and clinical applications
Shuo Yuan, Dandan Shen, Rui Jia, et al.
Medicinal Research Reviews (2023) Vol. 43, Iss. 6, pp. 2352-2391
Closed Access | Times Cited: 18
Association of Myelofibrosis Phenotypes with Clinical Manifestations, Molecular Profiles, and Treatments
Helen T. Chifotides, Srđan Verstovšek, Prithviraj Bose
Cancers (2023) Vol. 15, Iss. 13, pp. 3331-3331
Open Access | Times Cited: 14
Momelotinib in Myelofibrosis Patients With Thrombocytopenia: Post Hoc Analysis From Three Randomized Phase 3 Trials
Jean‐Jacques Kiladjian, Alessandro M. Vannucchi, Aaron T. Gerds, et al.
HemaSphere (2023) Vol. 7, Iss. 11, pp. e963-e963
Open Access | Times Cited: 13
Cytopenias and Large Splenomegaly are Main Drivers of Poor Outcome after Discontinuation of Ruxolitinib in Chronic Phase Myelofibrosis
Francesca Palandri, Massimo Breccia, Erika Morsia, et al.
(2025)
Closed Access
Disease phenotype significantly influences the outcome after discontinuation of ruxolitinib in chronic phase myelofibrosis.
Francesca Palandri, Massimo Breccia, Erika Morsia, et al.
Clinical Lymphoma Myeloma & Leukemia (2025)
Open Access
Inhibition of JAK2/STAT3 by pacritinib synergizes with chemotherapy in esophageal carcinoma
Lan Han, Yinyin Sun, Kai Yang, et al.
Toxicology in Vitro (2025), pp. 106056-106056
Closed Access
STAT3 Signaling Pathway in Health and Disease
Md Abdus Samad, Iftikhar Ahmad, A. M. Mahedi Hasan, et al.
MedComm (2025) Vol. 6, Iss. 4
Open Access
Inflammation as a Therapeutic Target in Cancer Cachexia
Gerald H. Clamon, Margaret M. Byrne, Erin E. Talbert
Cancers (2022) Vol. 14, Iss. 21, pp. 5262-5262
Open Access | Times Cited: 16
Synthesis and clinical application of new drugs approved by FDA in 2022
Jingyi Zhang, Yatao Wang, Lu Sun, et al.
Molecular Biomedicine (2023) Vol. 4, Iss. 1
Open Access | Times Cited: 9
Synthesis and clinical application of small-molecule inhibitors of Janus kinase
Jingyi Zhang, Jinfeng Sun, Peng Nie, et al.
European Journal of Medicinal Chemistry (2023) Vol. 261, pp. 115848-115848
Closed Access | Times Cited: 9
Pharmacological Profile of FDA-Approved Orphan Drugs in the Year 2022
Parveen Kumar Goyal, Kavita Sangwan
Current Pharmacology Reports (2024) Vol. 10, Iss. 2, pp. 96-120
Closed Access | Times Cited: 3
Recent Advances in IRAK1: Pharmacological and Therapeutic Aspects
Kyeong Min Kim, Na-Hee Hwang, Ja-Shil Hyun, et al.
Molecules (2024) Vol. 29, Iss. 10, pp. 2226-2226
Open Access | Times Cited: 3
A comprehensive review of new small molecule drugs approved by the FDA in 2022: Advance and prospect
Yi‐Ru Bai, Xin Yang, Ken Chen, et al.
European Journal of Medicinal Chemistry (2024) Vol. 277, pp. 116759-116759
Closed Access | Times Cited: 3
Benefit of Early Ruxolitinib Initiation Regardless of Fibrosis Grade in Patients with Primary Myelofibrosis: A Post Hoc Analysis of the Single-Arm Phase 3b JUMP Study
Francesca Palandri, Haifa Kathrin Al‐Ali, Paola Guglielmelli, et al.
Cancers (2023) Vol. 15, Iss. 10, pp. 2859-2859
Open Access | Times Cited: 8
SOHO State of the Art Updates and Next Questions: Novel Therapeutic Strategies in Development for Myelofibrosis
Helen T. Chifotides, Lucia Masárová, Srđan Verstovšek
Clinical Lymphoma Myeloma & Leukemia (2023) Vol. 23, Iss. 4, pp. 219-231
Open Access | Times Cited: 7
Pharmacological profile of novel anti-cancer drugs approved by USFDA in 2022: A Review
Kavita Sangwan, Vipasha Sharma, Parveen Kumar Goyal
Current Molecular Medicine (2023) Vol. 24, Iss. 6, pp. 734-750
Closed Access | Times Cited: 7
Recent advances in therapies for primary myelofibrosis
William Vainchenker, Nasrine Yahmi, Violaine Havelange, et al.
Faculty Reviews (2023) Vol. 12
Open Access | Times Cited: 7
Pacritinib inhibits proliferation of primary effusion lymphoma cells and production of viral interleukin-6 induced cytokines
Yiquan Wu, Victoria Wang, Robert Yarchoan
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 2
Nanodrug Delivery Strategies to Signaling Pathways in Alopecia
Xiaochuan Wu, Yong‐Zhong Du
Molecular Pharmaceutics (2023) Vol. 20, Iss. 11, pp. 5396-5415
Closed Access | Times Cited: 6
A year in pharmacology: new drugs approved by the US Food and Drug Administration in 2022
Gizem Kaykı-Mutlu, Zinnet Şevval Aksoyalp, Leszek Wojnowski, et al.
Naunyn-Schmiedeberg s Archives of Pharmacology (2023) Vol. 396, Iss. 8, pp. 1619-1632
Open Access | Times Cited: 5
Structural Analysis of Janus Tyrosine Kinase Variants in Hematological Malignancies: Implications for Drug Development and Opportunities for Novel Therapeutic Strategies
Omar J. Rodriguez Moncivais, Stephanie Chavez, Victor H. Estrada Jimenez, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 19, pp. 14573-14573
Open Access | Times Cited: 4
A sustainable approach for the determination of pacritinib in biological samples with dispersive liquid-liquid microextraction and using hydrophobic natural deep eutectic solvents
Natalia Treder, A.L. Kowal, Anna Roszkowska, et al.
Sustainable Chemistry and Pharmacy (2024) Vol. 42, pp. 101841-101841
Closed Access | Times Cited: 1
Analysis and therapeutic targeting of the IL-1R pathway in anaplastic large cell lymphoma
Zhihui Song, Wenjun Wu, Wei Wei, et al.
Blood (2023) Vol. 142, Iss. 15, pp. 1297-1311
Open Access | Times Cited: 3
Page 1 - Next Page

Scroll to top